A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach

Scientific Reports
Junzeng FuMei Wang

Abstract

The Chinese medicine Qiliqiangxin (QL) has been shown to have a protective role in heart failure. Here, we explore the underlying working mechanism of the key therapeutic component in QL using a rat model of heart failure. Heart failure after myocardial infarction was induced surgically and confirmed using echocardiography; a separate group of rats underwent sham surgery. The rats with heart failure were randomly assigned to receive QL, the angiotensin-converting enzyme inhibitor benazepril, or placebo groups. Blood samples were collected from the rats at four time points for up to 8 weeks and used for biochemical analysis and mass spectrometry‒based metabolomics profiling. In total, we measured nine well-known biochemical parameters of heart failure and 147 metabolites. In the rats with heart failure, QL significantly improved these biochemical parameters and metabolomics profiles, significantly increasing the cardioprotective parameter angiopoietin-like 4 and significantly lowering inflammation-related oxylipins and lysophosphatidic acids compared to benazepril. Mechanistically, QL may improve outcome in heart failure by controlling inflammatory process and cardiac hypertrophy. Clinical studies should be designed in order to ...Continue Reading

References

Aug 1, 1991·Clinical Cardiology·M MacNab, S Mallows
Jun 1, 1983·Journal of the American College of Cardiology·S R GoldsmithJ N Cohn
Feb 14, 1998·The American Journal of Cardiology·J LommiH Yki-Järvinen
Mar 17, 2004·Heart·Stefan D Anker, Stephan von Haehling
Mar 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Rafael Radi
Jun 1, 2005·Trends in Pharmacological Sciences·Pal PacherCsaba Szabó
May 28, 2008·Angiogenesis·Carol M Rivera-LopezKevin R Lynch
Jun 17, 2008·Biochimica Et Biophysica Acta·Yuko Fujiwara
Jun 28, 2008·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Y TadaD Nakae
Nov 11, 2008·Current Pharmaceutical Design·Giuseppe MarazziGiuseppe Mercuro
Jan 21, 2010·Physiological Reviews·Gary D LopaschukWilliam C Stanley
Mar 25, 2010·Prostaglandins & Other Lipid Mediators·Mu-En LinJerold Chun
Apr 5, 2011·Metabolomics : Official Journal of the Metabolomic Society·Maud M KoekThomas Hankemeier
Jul 21, 2012·Analytical and Bioanalytical Chemistry·Katrin StrassburgRob J Vreeken
Feb 8, 2013·Current Heart Failure Reports·Paraskevi DetopoulouSmaragdi Antonopoulou
Mar 20, 2013·Journal of Lipid Research·Andrew J Morris, Susan S Smyth
Aug 31, 2013·Circulation Research·Torsten DoenstE Dale Abel
Nov 14, 2013·Biochemical and Biophysical Research Communications·Elena MakoveichukGunilla Olivecrona
Nov 30, 2013·Cardiology Clinics·Gabriel Sayer, Geetha Bhat
Jan 31, 2014·Frontiers in Endocrinology·Gaetano Santulli
Sep 4, 2014·The New England Journal of Medicine·Chana A SacksGregory D Curfman

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
metabolomics profiling
ELISA

Software Mentioned

Adobe Illustrator
LabSolutions
Agilent MassHunter Quantitative Analysis
SPSS

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.